RYR2 and metabolic syndrome: Dysfunctional RyR2 and SERCA pump participate in the Ca2+ mishandling of MetS cardiomyocytes (i.e., reduced Ca2+ transient amplitude, and decreased Ca2+ spark-mediated Ca2+ leak), may account for the poor overall cardiac outcome reported in MetS patients and could be targeted for future therapies.